Maven Securities’s Cellectar Biosciences CLRB Stock Holding History

Maven Securities’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-833	Closed	-$48.8K	–	1089
2023 Q2	$48.8K	Hold	833	–	–	﹤0.01%	834
2023 Q1	$35.8K	Hold	833	–	–	﹤0.01%	897
2022 Q4	$42.8K	Hold	833	–	–	﹤0.01%	799
2022 Q3	$84K	Sell	833 -500	-38%	-$71.9K	﹤0.01%	1068
2022 Q2	$162K	Hold	1,333	–	–	﹤0.01%	856
2022 Q1	$275K	Hold	1,333	–	–	0.01%	727
2021 Q4	$266K	Sell	1,333 -2,038	-60%	-$491K	0.01%	718
2021 Q3	$935K	Buy	3,371 +1,204	+56%	+$367K	0.03%	471
2021 Q2	$793K	Sell	2,167 -833	-28%	-$361K	0.03%	505
2021 Q1	$1.45M	Sell	3,000 -2,750	-48%	-$1.63M	0.06%	289
2020 Q4	$3.71M	Buy	+5,750	New	+$2.64M	0.37%	64

Other funds holding CLRB

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Maven Securities's CLRB Position: Q3 2023 in Review

Maven Securities sold out of Cellectar Biosciences (CLRB) in Q3 2023, closing a stake of 833 shares — an estimated $48.8K sold.

Maven Securities first reported a position in CLRB in Q4 2020 and held it in 11 quarters. The position peaked at $3.71M in Q4 2020. 19 funds tracked by Wall St. Rank hold CLRB as of Q3 2023.

Maven Securities reported no remaining Cellectar Biosciences position as of Q3 2023 after selling out during the quarter.
Maven Securities sold 833 Cellectar Biosciences shares in Q3 2023, an estimated $48.8K.
Maven Securities first reported a position in Cellectar Biosciences in Q4 2020 and held it in 11 quarters.
Maven Securities's Cellectar Biosciences position peaked at $3.71M in Q4 2020.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2023.

Based on Maven Securities's 13F filing for Q3 2023, filed 13 Nov 2023.